Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX2 | P34913 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17510167 | 1.00 | EPHX2 (0.30) | EPHX2 | |
| SCHEMBL337473 | 1.00 | EPHX2 (0.30) | EPHX2 | |
| SCHEMBL12733072 | 0.93 | — | — | |
| SCHEMBL19339293 | 0.93 | — | — | |
| SCHEMBL1921189 | 0.85 | — | — | |
| SCHEMBL19346831 | 0.81 | ADH1A (0.35) | — | |
| SCHEMBL4569175 | 0.81 | — | — | |
| SCHEMBL23130634 | 0.81 | — | — | |
| SCHEMBL29118945 | 0.78 | — | — | |
| SCHEMBL4456910 | 0.76 | EPHX2 (0.33) | EPHX2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 69 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12612380-B2 | Non-lysosomal glucosylceramidase inhibitors and uses thereof | ALECTOS THERAPEUTICS 1NC (CA) | 2026-04-28 | — | — | US | disclosed |
| EP-3966199-B1 | NON-LYSOSOMAL GLUCOSYLCERAMIDASE INHIBITORS AND USES THEREOF | ALECTOS THERAPEUTICS INC (CA) | 2026-03-18 | — | — | EP | disclosed |
| US-12570625-B2 | 3-(5-hydroxy-1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives and uses thereof | NOVARTIS AG (CH) | 2026-03-10 | — | — | US | disclosed |
| US-12479817-B2 | Substituted 3-(1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives and uses thereof | NOVARTIS AG (CH) | 2025-11-25 | — | — | US | disclosed |
| US-20250282762-A1 | PYRAZOLOPYRIDINE DERIVATIVES AND USES THEREOF | NOVARTIS AG (CH) | 2025-09-11 | — | — | US | disclosed |
| US-12252482-B2 | Pyrazolopyridine derivatives and uses thereof | NOVARTIS AG (CH) | 2025-03-18 | — | — | US | disclosed |
| US-20250002479-A1 | PYRAZOLOPYRIDINE DERIVATIVES AND USES THEREOF | NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH, INC. | 2025-01-02 | — | — | US | disclosed |
| US-12172984-B2 | Pyrazolopyridine derivatives and uses thereof | NOVARTIS AG (CH) | 2024-12-24 | — | — | US | disclosed |
| US-20240158374-A1 | Pyrazolopyridine Derivatives and Uses thereof | NOVARTIS AG (CH) | 2024-05-16 | — | — | US | disclosed |
| EP-4076650-B1 | 3-(5-METHOXY-1-OXOISOINDOLIN-2-YL)PIPERIDINE-2,6-DIONE DERIVATIVES AND USES THEREOF | NOVARTIS AG (CH) | 2024-02-28 | — | — | EP | disclosed |
| US-9624217-B2 | Dihydropyrrolopyridine inhibitors of ROR-gamma | VITAE PHARMACEUTICALS, INC. (US) | 2017-04-18 | — | — | US | disclosed |
| US-9624217-B2 | Dihydropyrrolopyridine inhibitors of ROR-gamma | VITAE PHARMACEUTICALS, INC. (US) | 2017-04-18 | — | — | US | disclosed |
| US-20160200724-A1 | DIHYDROPYRROLOPYRIDINE INHIBITORS OF ROR-GAMMA | VITAE PHARMACEUTICALS, LLC | 2016-07-14 | — | — | US | disclosed |
| US-20160200724-A1 | DIHYDROPYRROLOPYRIDINE INHIBITORS OF ROR-GAMMA | VITAE PHARMACEUTICALS, LLC | 2016-07-14 | — | — | US | disclosed |
| US-9266886-B2 | Dihydropyrrolopyridine inhibitors of ROR-gamma | VITAE PHARMACEUTICALS, INC. (US) | 2016-02-23 | — | — | US | disclosed |
| US-9266886-B2 | Dihydropyrrolopyridine inhibitors of ROR-gamma | VITAE PHARMACEUTICALS, INC. (US) | 2016-02-23 | — | — | US | disclosed |
| US-20150218160-A1 | DIHYDROPYRROLOPYRIDINE INHIBITORS OF ROR-GAMMA | VITAE PHARMACEUTICALS, LLC | 2015-08-06 | — | — | US | disclosed |
| WO-2015116904-A1 | DIHYDROPYRROLOPYRIDINE INHIBITORS OF ROR-GAMMA | VITAE PHARMACEUTICALS, INC. (US) | 2015-08-06 | — | — | WO | disclosed |
| US-20150218160-A1 | DIHYDROPYRROLOPYRIDINE INHIBITORS OF ROR-GAMMA | VITAE PHARMACEUTICALS, LLC | 2015-08-06 | — | — | US | disclosed |
| CN-103025725-A | Heterocyclic compounds | ASTELLAS PHARMA INC | 2013-04-03 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12172984-B2 | Pyrazolopyridine derivatives and uses thereof | HBZ, ZFX, WIZ | EPHX2 2949/4885 |
| US-12252482-B2 | Pyrazolopyridine derivatives and uses thereof | HBZ, ZFX, WIZ | EPHX2 2949/4885 |
| US-20250282762-A1 | PYRAZOLOPYRIDINE DERIVATIVES AND USES THEREOF | HBZ, ZFX, WIZ | EPHX2 2949/4885 |
| US-12479817-B2 | Substituted 3-(1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives and uses thereof | XDH, RXFP3, NPY2R | EPHX2 2457/4885 |
| US-12570625-B2 | 3-(5-hydroxy-1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives and uses thereof | IKZF1, IKZF2, BCL6 | EPHX2 3188/4885 |
| US-12612380-B2 | Non-lysosomal glucosylceramidase inhibitors and uses thereof | GBA1, GBA2, MAN2B1 | EPHX2 1539/4885 |
| US-20240158374-A1 | Pyrazolopyridine Derivatives and Uses thereof | HBZ, ZFX, WIZ | EPHX2 2949/4885 |
| US-20160200724-A1 | DIHYDROPYRROLOPYRIDINE INHIBITORS OF ROR-GAMMA | RORC, RORB, RORA | EPHX2 1845/4885 |
| US-20250002479-A1 | PYRAZOLOPYRIDINE DERIVATIVES AND USES THEREOF | HBZ, ZFX, WIZ | EPHX2 2949/4885 |
| US-20150218160-A1 | DIHYDROPYRROLOPYRIDINE INHIBITORS OF ROR-GAMMA | RORC, RORB, RORA | EPHX2 1845/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.